NIKKEI 225
39,046.52 +429.42 (+1.11%) HANG SENG
18,871.65 -323.95 (-1.69%) CRUDE OIL
76.93 -0.64 (-0.83%) GOLD FUTURES
2,368.70 -24.20 (-1.01%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,511.02 -365.32 (-0.67%)
Pfizer Inc (PFE.HA)
| Previous close | 26.20 |
| Open | 26.32 |
| Bid | 27.34 x 0 |
| Ask | 27.37 x 0 |
| Day's range | 26.32 - 26.32 |
| 52-week range | 23.64 - 37.35 |
| Volume | |
| Avg. volume | 75 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BloombergSecond US Human Bird Flu Infection Reported in Michigan
(Bloomberg) -- A Michigan farmworker tested positive with bird flu, the second person to contract the potentially lethal virus that has run rampant in US cattle.Most Read from BloombergThese Flight Routes Suffer the World’s Worst TurbulenceNvidia Delivers on AI Hopes, Igniting $140 Billion Stock RallyCiti Trader Got 711 Warning Messages Before Sparking Flash CrashTech Up in Late Hours as Nvidia Emboldens AI Bulls: Markets WrapThe farmworker experienced mild symptoms in the eye after contact with
Barrons.comCDC Confirms a Second Bird Flu Case in U.S. Dairy Worker. Vaccine Momentum Builds.
U.S. officials said Wednesday that a Michigan dairy worker had tested positive for avian influenza, the second known human case in the U.S. since the virus was detected in late March in cattle. The Centers for Disease Control and Prevention said that the patient only had eye symptoms, similar to the first known infected dairy worker, who developed conjunctivitis in Texas in March. The CDC said that it still considers the risk from the current outbreak to the general public to be low.
ReutersPfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
Investors have fled from Pfizer as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared. Pfizer's shares were up 2.6% at $29.30 in afternoon trading. Pfizer made the disclosure on Wednesday in a filing with the Securities and Exchange Commission.
